Sudeep Pharma wraps FY26 with 28% revenue growth, 26% PAT jump
Audited annual numbers confirm strong speciality ingredients demand and NSS Ireland contribution; final dividend of ₹1.50 per share recommended.
— 1 earlier story on Sudeep Pharma Ltd. →What's new with Sudeep Pharma Ltd.
- Revenue up ~28% YoY to ₹642 cr; PAT up ~26% to ₹174 cr.
- Board recommends final dividend of ₹1.50 per share.
- Speciality ingredients segment and NSS Ireland acquisition drove performance.
Why this matters for Sudeep Pharma Ltd.
The numbers are strong, but this is a routine annual filing — the trajectory was already signalled in prior quarterly updates. The dividend is a modest return of capital. What matters for next year is whether the speciality ingredients run-rate can sustain.
What we're watching
- Full-year management commentary on demand visibility in speciality ingredients.
- NSS Ireland integration progress and margin contribution.
- Capex plan for FY27.
The full read
Sudeep Pharma closed FY26 with consolidated revenue of ₹642 crore, up 28%, and PAT of ₹174 crore, up 26%. The speciality ingredients segment and the NSS Ireland buy both pulled their weight — the same factors that drove the quarterly beats. The board also recommended a ₹1.50 final dividend. This is a clean annual filing, but nothing here is new: the trajectory was visible after Q3. The real question is whether the growth levers — speciality demand, Ireland capacity — have room to run, or whether FY27 starts on a tougher comp.